Examining the large intestine with a camera capsule in patients with blood infections from gut bacteria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to diagnose colorectal cancer and precancerous tumors in patients over 18 years old who are hospitalized with blood stream infections caused by anaerobic gut-associated bacteria. Participants will undergo colon capsule endoscopy 4-8 weeks after discharge to assess the prevalence of cancer and precancerous lesions in their large intestines and rectum. The study focuses on understanding the link between anaerobic bacteremia and colorectal malignancies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Older than 18 years
* Blood culture with growth of one or more of the following bacterial genera Bacteroides, Clostridium, Filifactor, Fusobacterium, Gemella, Granulicatella, Parvimonas, Peptostreptococcus, Prevotella, Solobacterium, Peptoniphilus, Ruminococcus, Finegoldia and Streptococcus.
* Able to provide oral and written informed consent
* Able to read and speak Danish

Exclusion Criteria:

* Prior colorectal cancer diagnosis
* History of stenosis of the gastrointestinal tract
* Previous treatment of inflammatory bowel disease
* Previous major surgery of the gastrointesinal tract (e.g. gastric bypass)
* Colostomy
* Pacemaker/ICD
* Pregnancy or breastfeeding
* Allergies to the bowel preparation regimen
* Severe kidney disease
* Focus of infection in skin and soft tissue or outside the truncus (e.g. decubitus, diabetic foot ulcer)
* Tumor in the colon or rectum at diagnostic imaging
* Transfer to other hospital outside the region

Where it's running

• Odense University Hospital
  Odense, Denmark Recruiting

Study contacts

• Study coordinator: Charlotte Nielsen Agergaard, MD
• Email: charlotte.agergaard@rsyd.dk
• Phone: 004565414797

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• UllCORE BSI Test for Bloodstream Infections

  This study tests whether the UllCORE BSI Test can correctly detect bloodstream infection pathogens and resistance markers from whole blood in people with suspected infection or sepsis.

  Recruiting Deepull Diagnostics S.L. · Orange, California and 19 other locations · NCT07859852

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Pirfenidone plus PD-1 inhibitor with or without targeted radiotherapy for advanced colorectal cancer

  This study tests whether combining pirfenidone with a PD-1 inhibitor, with or without hypofractionated radiotherapy, is safe and helps people with unresectable or metastatic pMMR/MSS colorectal cancer who have exhausted standard therapies.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07644286

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.